SARS News and Research

RSS

COVID-19 prevention strategies may have led to a decrease in common respiratory infections

Wearing masks and physical distancing - two key infection prevention strategies implemented to stop the spread of COVID-19 - may have led to the dramatic decrease in rates of common respiratory viral infections, such as influenza.

23 Mar 2021

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

All viruses mutate as they make copies of themselves to spread and thrive. SARS-CoV-2, the virus the causes COVID-19, is proving to be no different. There are currently more than 4,000 variants of COVID-19, which has already killed more than 2.7 million people worldwide during the pandemic.

23 Mar 2021

Post-COVID-19 blood clots may be caused by lingering immune response in blood vessels

Serious complications due to blood clots, such as heart attacks and strokes, that are experienced by some COVID-19 survivors may be caused by a lingering immune response in the blood vessels after recovery, suggests a study published today in eLife.

23 Mar 2021

Study reveals a genetic variant linked to COVID-19 severity in young men

A study of young men with COVID-19 has revealed a genetic variant linked to disease severity.

23 Mar 2021

Pfizer coronavirus vaccine found to be moderately less effective against South African variant

Ben-Gurion University of the Negev (BGU) researchers have found that the Pfizer Coronavirus vaccine is moderately less effective against the South African variant, but still neutralizes the British variant and the original SARS-CoV-2 strain.

23 Mar 2021

Is T-cell receptor sequencing a reliable alternative to SARS-CoV-2 antibody testing?

Researchers in the United States have now demonstrated that T-cell receptor (TCR) sequencing might provide a reliable alternative to assessing infection in convalescent blood plasma, and may be applicable in the future for applying protective immunity to individuals.

23 Mar 2021

Correlation of antibody titers with COVID-19 vaccine efficacy

In a new study the relationship between virus-neutralizing antibody and spike protein-binding IgG antibody levels is explored following vaccination by one of seven currently deployed vaccines. The findings support the use of antibody titers as correlates of protection for COVID-19 vaccines.

23 Mar 2021

COVID-19 vaccines reduce virus transmission in healthcare worker case study

In a new study, the ability of COVID-19 vaccines to lessen transmission was examined in a large study of healthcare workers and their families, with promising results that indicate a substantially reduced rate of transmission from the vaccinated to the non-vaccinated.

23 Mar 2021

Immunoassay heterogeneity and implications for SARS-CoV-2 serosurveillance

In a recent study, scientists have quantified anti-SARS-CoV-2 antibody levels up to 9 months after infection.

23 Mar 2021

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

A Korea-based company EyeGene Inc. has recently developed a liposome-based mRNA candidate vaccine against COVID-19, which contains full-length spike protein of the European variant (D614G) of SARS-CoV-2 as a vaccine antigen.

23 Mar 2021

COVID-19 antibodies can protect against reinfection for at least eight months

A new study offers hope that recovered patients from COVID-19 are largely immune to reinfection for at least eight months.

23 Mar 2021

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

A new study addresses the issue of passive immunity to SARS-CoV-2 for newborns via breast milk.

23 Mar 2021

Dandelion extract inhibits SARS-CoV-2 in vitro

An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.

23 Mar 2021

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

IONTAS Limited (IONTAS) and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimization of fully human antibodies, have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants.

From FairJourney Biologics 23 Mar 2021

Researchers use new approach to detect COVID-19 in wastewater

There are many ways to test municipal wastewater for signs of the virus that causes COVID-19, but scientists in Houston have determined theirs is the best yet.

23 Mar 2021

Study reveals heightened mortality and racial disparities for cancer patients diagnosed with COVID-19

The COVID-19 and Cancer Consortium (CCC19) published new findings in the Annals of Oncology, showing heightened mortality and racial disparities for patients with cancer diagnosed with SARS-CoV-2 infection.

23 Mar 2021

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Recently, researchers from the US employed multiple-µs molecular dynamic simulations to compare the relative dynamics, stabilities, and energy differences between the SARS-CoV receptor-binding domain (RBD)-ACE2 and SARS-CoV-2 RBD-ACE2 complexes. The study is published on the preprint server, bioRxiv.

23 Mar 2021

Swiss research shows clusters of SARS-CoV-2 infection are rare within school classes

Researchers from Switzerland recently presented the results of a longitudinal cohort study they conducted in the city of Zurich. The prospective cohort study's key objective was to analyze the longitudinal changes in SARS-CoV-2 seroprevalence and assess the clustering of seropositive children in school classes from June to November 2020 in Zurich, Switzerland.

23 Mar 2021

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

In a paper recently uploaded to the preprint server bioRxiv by Tauzin et al. (March 18th, 2021) the ability of a single dose of mRNA vaccine to induce humoral and T cell responses against mutated variants are demonstrated and found to be reinforced in individuals with a history of COVID-19.

22 Mar 2021

Simple SARS-CoV-2 mutations allow escape from the majority of polyclonal antibodies

The group identified a single class of antibodies that target a particular epitope on the RBD of SARS-CoV-2, suggesting that the human polyclonal response to SARS-CoV-2 infection is dominated by a worryingly narrow range of antibodies that target an epitope undergoing rapid mutation.

22 Mar 2021

SARS News and Research

COVID-19 prevention strategies may have led to a decrease in common respiratory infections

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

Post-COVID-19 blood clots may be caused by lingering immune response in blood vessels

Study reveals a genetic variant linked to COVID-19 severity in young men

Pfizer coronavirus vaccine found to be moderately less effective against South African variant

Is T-cell receptor sequencing a reliable alternative to SARS-CoV-2 antibody testing?

Correlation of antibody titers with COVID-19 vaccine efficacy

COVID-19 vaccines reduce virus transmission in healthcare worker case study

Immunoassay heterogeneity and implications for SARS-CoV-2 serosurveillance

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

COVID-19 antibodies can protect against reinfection for at least eight months

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

Dandelion extract inhibits SARS-CoV-2 in vitro

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

Researchers use new approach to detect COVID-19 in wastewater

Study reveals heightened mortality and racial disparities for cancer patients diagnosed with COVID-19

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Swiss research shows clusters of SARS-CoV-2 infection are rare within school classes

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

Simple SARS-CoV-2 mutations allow escape from the majority of polyclonal antibodies

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News